中性粒细胞CD64指数指导慢性阻塞性肺疾病急性加重期抗生素应用的探讨(1)
摘要：目的 研究CD64指数在减少慢性阻塞性肺疾病急性加重期(AECOPD)患者抗生素应用中的意义。方法 选取2017年1月～10月入住我院的120例AECOPD患者，隨机分为对照组和实验组，各60例。对照组根据2016年GOLD指南使用抗生素，实验组根据入院2 h内CD64指数水平来决定是否使用抗生素，在第4天、第8天复测CD64指数水平，若第8天CD64指数≤3，则停用抗生素，相反则继续使用抗生素。比较两组不同时间CD64指数、出院时相关指标(临床有效率、抗生素使用时间、住院时间、平均抗生素花费)、出院后1年内相关指标包括：至下次急性加重时间、随访1年内急性加重次数、住院次数及第一秒用力呼气容积(FEV1)变化。结果 治疗后第4天和第8天，实验组CD64指数水平分别为(1.84±0.65)、(0.86±0.05)，对照组CD64指数水平分别为(2.52±0.30)、(1.45±0.03)均较入院时的(3.47±1.00)、(3.04±1.12)降低，且实验组CD64指数在治疗后第4天和第8天均低于对照组，差异有统计学意义(P<0.05);②实验组抗生素使用时间、住院时间、平均抗生素花费均少于对照组，差异有统计学意义(P<0.05);两组的临床有效率、至下次急性加重时间、随访1年内急性加重次数、住院次数及FEV1变化比较，差异无统计学意义(P>0.05)。结论 CD64指数可有助于决定AECOPD患者是否使用抗生素，对AECOPD患者抗生素的使用有重要的指导意义
, http://www.100md.com
关键词：慢性阻塞性肺疾病;急性加重期;CD64指数;抗生素
中图分类号：R563 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.07.023
文章编号：1006-1959(2019)07-0078-04
Abstract：Objective To study the significance of CD64 index in reducing antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 120 AECOPD patients admitted to our hospital from January to October 2017 were randomly divided into control group and experimental group， 60 cases each. The control group used antibiotics according to the 2016 GOLD guidelines. The experimental group decided whether to use antibiotics according to the CD64 index level within 2 hours after admission. The CD64 index level was retested on the 4th and 8th days. If the CD64 index was ≤3 on the 8th day， Stop using antibiotics and instead continue to use antibiotics. The CD64 index and discharge-related indicators (clinical efficacy， antibiotic use time， hospitalization time， and average antibiotic cost) were compared between the two groups. The relevant indicators within 1 year after discharge included： the time of the next acute exacerbation， and the number of acute exacerbations within 1 year of follow-up. The number of hospitalizations and the forced expiratory volume (FEV1) in the first second were changed. Results On the 4th day and the 8th day after treatment， the CD64 index levels of the experimental group were (1.84±0.65) and (0.86±0.05)， respectively. The CD64 index levels of the control group were (2.52±0.30) and (1.45±0.03)， respectively. At the time of admission， (3.47±1.00) and (3.04±1.12) were decreased， and the CD64 index of the experimental group was lower than that of the control group on the 4th and 8th day after treatment， the difference was statistically significant (P<0.05);②Experiment The time of antibiotic use， hospitalization time and average antibiotic cost were lower than the control group， the difference was statistically significant (P<0.05); the clinical effective rate of the two groups， the time of the next acute exacerbation， the number of acute exacerbations within 1 year of follow-up， hospitalization，there was no significant difference in the number of times and changes in FEV1(P>0.05). Conclusion The CD64 index can help determine whether AECOPD patients use antibiotics， which has important guiding significance for the use of antibiotics in AECOPD patients., 百拇医药(张佳佳 李庆 王同)
, http://www.100md.com
关键词：慢性阻塞性肺疾病;急性加重期;CD64指数;抗生素
中图分类号：R563 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.07.023
文章编号：1006-1959(2019)07-0078-04
Abstract：Objective To study the significance of CD64 index in reducing antibiotics in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD). Methods A total of 120 AECOPD patients admitted to our hospital from January to October 2017 were randomly divided into control group and experimental group， 60 cases each. The control group used antibiotics according to the 2016 GOLD guidelines. The experimental group decided whether to use antibiotics according to the CD64 index level within 2 hours after admission. The CD64 index level was retested on the 4th and 8th days. If the CD64 index was ≤3 on the 8th day， Stop using antibiotics and instead continue to use antibiotics. The CD64 index and discharge-related indicators (clinical efficacy， antibiotic use time， hospitalization time， and average antibiotic cost) were compared between the two groups. The relevant indicators within 1 year after discharge included： the time of the next acute exacerbation， and the number of acute exacerbations within 1 year of follow-up. The number of hospitalizations and the forced expiratory volume (FEV1) in the first second were changed. Results On the 4th day and the 8th day after treatment， the CD64 index levels of the experimental group were (1.84±0.65) and (0.86±0.05)， respectively. The CD64 index levels of the control group were (2.52±0.30) and (1.45±0.03)， respectively. At the time of admission， (3.47±1.00) and (3.04±1.12) were decreased， and the CD64 index of the experimental group was lower than that of the control group on the 4th and 8th day after treatment， the difference was statistically significant (P<0.05);②Experiment The time of antibiotic use， hospitalization time and average antibiotic cost were lower than the control group， the difference was statistically significant (P<0.05); the clinical effective rate of the two groups， the time of the next acute exacerbation， the number of acute exacerbations within 1 year of follow-up， hospitalization，there was no significant difference in the number of times and changes in FEV1(P>0.05). Conclusion The CD64 index can help determine whether AECOPD patients use antibiotics， which has important guiding significance for the use of antibiotics in AECOPD patients., 百拇医药(张佳佳 李庆 王同)